Hi Sharp has successfully deployed its latest SVR solution in Japan and Taiwan, reinforcing AI technology implementation in both markets. TAIPEI and NEW YORK, Jan. 26, 2024 /PRNewswire/ — Hi Sharp, a leading maker of NDAA-compliant surveillance camera systems, has officially announced its AI-powered, multi-use surveillance platform – SVR. Slated for release in Q2 2024, the platform… Continue reading The Future Arrives in 2024 Security Led by Hi Sharp’s Flagship SVR
Category: Newswire
The Place for Children with Autism Announces Opening of Jefferson Park Location
CHICAGO, Jan. 26, 2024 /PRNewswire/ — The Place for Children with Autism, a leading provider of Applied Behavior Analysis (ABA) therapy for children on the spectrum, announces the opening of a new center in Jefferson Park, IL. The new center is set to follow the same model as the locations currently in operation throughout the Chicagoland… Continue reading The Place for Children with Autism Announces Opening of Jefferson Park Location
The Future Arrives in 2024 Security Led by Hi Sharp’s Flagship SVR
Hi Sharp has successfully deployed its latest SVR solution in Japan and Taiwan, reinforcing AI technology implementation in both markets. TAIPEI and NEW YORK, Jan. 26, 2024 /PRNewswire/ — Hi Sharp, a leading maker of NDAA-compliant surveillance camera systems, has officially announced its AI-powered, multi-use surveillance platform – SVR. Slated for release in Q2 2024, the platform… Continue reading The Future Arrives in 2024 Security Led by Hi Sharp’s Flagship SVR
Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium
–First-in-human trial evaluating safety, tolerability, and clinical activity of FX-909 in patients with advanced solid malignancies including advanced urothelial carcinoma– CAMBRIDGE, Mass., Jan. 26, 2024 /PRNewswire/ — Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, today announced a poster presentation outlining the Phase 1… Continue reading Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium
JA Solar behält die höchste AAA-Bewertung in der PV ModuleTech-Bankability-Rangliste
BEIJING, 26. Januar 2024 /PRNewswire/ — JA Solar hat sein AAA-Ranking im neuesten PV ModuleTech-Bankability-Bericht für das vierte Quartal 2023 beibehalten, was den Status des Unternehmens in Bereichen wie Herstellung, Lieferungen, Kapazitäts- und Technologieauslegung und finanzielle Leistung widerspiegelt. Continue Reading JA Solar maintains highest AAA rating in PV ModuleTech bankability rankings Das Unternehmen hat sich… Continue reading JA Solar behält die höchste AAA-Bewertung in der PV ModuleTech-Bankability-Rangliste
Kirkland’s Home Secures $12 Million in Additional Debt Financing to Support Strategic Repositioning Efforts
NASHVILLE, Tenn., Jan. 26, 2024 /PRNewswire/ — Kirkland’s, Inc. (Nasdaq: KIRK) (“Kirkland’s Home” or the “Company”), a specialty retailer of home décor and furnishings, entered into a supplemental credit facility on January 25, 2024, which will increase its available credit by up to $12 million. To support its strategic repositioning efforts, Kirkland’s Home secured additional… Continue reading Kirkland’s Home Secures $12 Million in Additional Debt Financing to Support Strategic Repositioning Efforts
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Jan. 26, 2024 /PRNewswire/ — Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has entered into a licensing agreement with CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (“Cristália”), for exclusive Brazilian rights to the commercialization of APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for the treatment of inflammation and pain following ocular surgery. APP13007 is… Continue reading Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
Panacea Financial Named Exclusive Practice Finance Provider for American Dental Association Members across the United States
Panacea Financial to provide ADA members with financial products and services to help dental practices thrive. LITTLE ROCK, Ark., Jan. 26, 2024 /PRNewswire/ — Panacea Financial and ADA Member Advantage, a wholly owned subsidiary of the American Dental Association, announced today that Panacea has been selected as the newly endorsed and exclusively recommended practice finance… Continue reading Panacea Financial Named Exclusive Practice Finance Provider for American Dental Association Members across the United States
Autoliv: Financial Report October – December 2023
STOCKHOLM, Jan. 26, 2024 /PRNewswire/ — (NYSE: ALV) and (SSE: ALIV.sdb) Q4 2023: Record sales and strong profitability Financial highlights Q4 2023 $2,751 million net sales 18% net sales increase 16% organic sales growth* 8.6% operating margin 12.1% adjusted operating margin* $2.71 EPS, 51% increase $3.74 adjusted EPS*, 105% increase Full year 2024 guidance Around 5% organic… Continue reading Autoliv: Financial Report October – December 2023
Autoliv: Financial Report October – December 2023
STOCKHOLM, Jan. 26, 2024 /PRNewswire/ — (NYSE: ALV) and (SSE: ALIV.sdb) Q4 2023: Record sales and strong profitability Financial highlights Q4 2023 $2,751 million net sales 18% net sales increase 16% organic sales growth* 8.6% operating margin 12.1% adjusted operating margin* $2.71 EPS, 51% increase $3.74 adjusted EPS*, 105% increase Full year 2024 guidance Around 5% organic… Continue reading Autoliv: Financial Report October – December 2023